Clinical Trial Update: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib mesylate for patients with unresectable stage III or stage IV melanoma, including acral lentiginous melanoma; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Lentiginous Melanoma
• Melanoma

Drugs mentioned

• Imatinib Mesylate (Gleevec) (Imatinib mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acral Lentiginous Malignant Melanoma, Recurrent Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2014-12-23